Self-Assembly Liver Acinus Model for Human Pharmacokinetics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current liver models for drug discovery and safety testing are limited by poor correlation with human liver effects, difficulty in obtaining high-quality human liver tissue, inability to replicate key liver functions like fibrosis and immune response, and short functional lifetimes, which restrict their ability to predict pharmacokinetics, toxicity, and efficacy in humans.
Innovation Solution
A self-assembly 3D microfluidic liver acinus model (SALA) and human liver microphysiology platform (HLMP) that uses multiple human cell types to recreate liver tissue in a microfluidic device, incorporating genetically encoded fluorescence-based biosensors for real-time measurements and data analysis, allowing for long-term maintenance and prediction of human liver interactions with compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If simple 2D models are used, then ease of manufacture and operation are improved, but the ability to replicate key liver functions such as fibrosis and immune response deteriorates
Solution Approach 1:
The patent transitions from traditional 2D cell culture models to a 3D microphysiological system. The liver acinus model uses three-dimensional cell assemblies that self-organize within a microfluidic device, enabling replication of complex liver functions including fibrosis and immune response while maintaining manufacturability through standardized microfabrication processes.
Solution Approach 2:
The model employs a composite structure combining multiple cell types (hepatocytes, endothelial cells, Kupffer cells, stellate cells) with extracellular matrix materials to create a functional liver acinus. This composite approach enables the system to replicate multiple liver functions simultaneously, including metabolism, immune response, and fibrosis, while maintaining ease of manufacture through standardized cell culture and assembly protocols.
2Measurement precision
If human liver tissue is obtained from surgical sources, then measurement precision and reliability are improved, but ease of manufacture and availability deteriorate due to difficulty in obtaining and variable quality
Solution Approach 1:
The patent creates in vitro copies of human liver tissue using cell cultures that replicate the structure and function of native liver acini. These copied systems maintain the physiological relevance needed for accurate predictions while eliminating the limitations of surgical tissue sources, providing unlimited availability and consistent quality through standardized cell culture methods.
Solution Approach 2:
The model uses induced pluripotent stem cells (iPSCs) that can be differentiated into various liver cell types, allowing control over cell parameters such as purity, functionality, and genetic background. This parameter control enables consistent production of high-quality liver models with predictable performance, overcoming the variability inherent in surgical tissue samples.
3Ease of operation
If traditional in vitro models are used, then ease of operation is improved, but duration of action deteriorates due to short functional lifetime of approximately 2 weeks
Solution Approach 1:
The patent implements a continuous flow system within the microfluidic device that maintains physiological conditions for the liver acinus model. The perfused culture system continuously delivers nutrients and removes waste products, enabling the model to maintain functional viability for extended periods (at least one month) while remaining easy to operate through automated fluid handling.
Solution Approach 2:
The liver acinus model exhibits self-organizing properties where cells automatically form functional structures and maintain their own microenvironment. This self-service capability reduces the need for frequent manual intervention and media changes, extending the functional lifetime of the model while maintaining ease of operation through reduced maintenance requirements.
4Ease of manufacture
If lab animal models are used, then ease of manufacture and availability are improved, but measurement precision deteriorates due to poor correlation with human liver drug effects
Solution Approach 1:
The patent creates human-specific in vitro models that copy human liver physiology directly, eliminating the need for animal models. By using human-derived cells (primary hepatocytes, iPSC-derived hepatocytes, human endothelial cells, human Kupffer cells, human stellate cells), the system maintains high availability through standardized cell culture while achieving superior measurement precision through direct human physiological relevance.
Data Source
AI summary
Microfluidic devices for modeling three-dimensional tissue structures and methods for making and using the same are described herein.